Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $6.8 million.

  • Theravance Biopharma's Prepaid Assets fell 1207.5% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 1207.5%. This contributed to the annual value of $4.3 million for FY2024, which is 6313.88% down from last year.
  • Per Theravance Biopharma's latest filing, its Prepaid Assets stood at $6.8 million for Q3 2025, which was down 1207.5% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Prepaid Assets ranged from a high of $12.4 million in Q2 2021 and a low of $4.1 million during Q1 2025
  • Its 5-year average for Prepaid Assets is $7.6 million, with a median of $7.7 million in 2024.
  • Its Prepaid Assets has fluctuated over the past 5 years, first surged by 8279.0% in 2021, then tumbled by 6313.88% in 2024.
  • Quarter analysis of 5 years shows Theravance Biopharma's Prepaid Assets stood at $8.6 million in 2021, then fell by 10.27% to $7.7 million in 2022, then soared by 51.04% to $11.6 million in 2023, then plummeted by 63.14% to $4.3 million in 2024, then surged by 57.82% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $5.6 million for Q2 2025, and $4.1 million during Q1 2025.